Chengzhan Zhu, Bingzi Dong, Xin Chen, Qian Dong. Diagnosis and Treatment of Hepatoblastoma: An Update. In: Vijay Gayam, Omer Engin, editors. Liver Pathology [Internet]. Rijeka: IntechOpen; 2020 [cited 2024 May 20]. p. Ch. 1. Available from: https://doi.org/10.5772/intechopen.90830

Feng J, Polychronidis G, Heger U, Frongia G, Mehrabi A, Hoffmann K. Incidence trends and survival prediction of hepatoblastoma in children: a population-based study. Cancer Commun (Lond). 2019;39:62

PubMed  Google Scholar 

Wu PV, Rangaswami A. Current approaches in hepatoblastoma-new biological insights to inform therapy. Curr Oncol Rep. 2022;24:1209–1218

Article  CAS  PubMed  Google Scholar 

Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003;38:560–566

Article  PubMed  Google Scholar 

Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992–2004). Cancer. 2008;112:416–432

Article  PubMed  Google Scholar 

Hadzic N, Finegold MJ. Liver neoplasia in children. Clin Liver Dis. 2011;15(443–62):vii–x

Google Scholar 

Hung G-Y, Horng J-L, Lee Y-S, Yen H-J, Chen C-C, Lee C-Y. Cancer incidence patterns among children and adolescents in Taiwan from 1995 to 2009: a population-based study. Cancer. 2014;120:3545–3553

Article  PubMed  Google Scholar 

Dembowska-Bagińska B, Więckowska J, Brożyna A, Święszkowska E, Ismail H, Broniszczak-Czyszek D, et al. Health status in long-term survivors of hepatoblastoma. Cancers. 2019;11:1777

Article  PubMed  PubMed Central  Google Scholar 

Towbin AJ, Meyers RL, Woodley H, Miyazaki O, Weldon CB, Morland B, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 2018;48:536–554

Article  PubMed  Google Scholar 

Czauderna P, Haeberle B, Hiyama E, Rangaswami A, Krailo M, Maibach R, et al. The Children’s Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92–101

Article  PubMed  Google Scholar 

Kahla JA, Siegel DA, Dai S, Lupo PJ, Foster JH, Scheurer ME, et al. Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. Pediatr Blood Cancer. 2022;69: e29763

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhakta N, Force LM, Allemani C, Atun R, Bray F, Coleman MP, et al. Childhood cancer burden: a review of global estimates. Lancet Oncol. 2019;20:e42-53

Article  PubMed  Google Scholar 

GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133–2161.

GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;S0140–6736(24)00367–2.

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22.

Frick C, Rumgay H, Vignat J, Ginsburg O, Nolte E, Bray F, et al. Quantitative estimates of preventable and treatable deaths from 36 cancers worldwide: a population-based study. Lancet Glob Health. 2023;11:e1700–e1712

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang K, Kan C, Han F, Zhang J, Ding C, Guo Z, et al. Global, Regional, and National Epidemiology of Diabetes in Children From 1990 to 2019. JAMA Pediatr. 2023;177:837–846

Article  PubMed  PubMed Central  Google Scholar 

Heck JE, Meyers TJ, Lombardi C, Park AS, Cockburn M, Reynolds P, et al. Case-control study of birth characteristics and the risk of hepatoblastoma. Cancer Epidemiol. 2013;37:390–395

Article  PubMed  PubMed Central  Google Scholar 

de Fine LS, Schmidt LS, Rod NH, Schmiegelow K, Lähteenmäki PM, Kogner P, et al. Hepatoblastoma in the Nordic countries. Int J Cancer. 2012;131:E555-561

Google Scholar 

Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, et al. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births. JAMA Oncol. 2019;5:1150–1158

Article  PubMed  Google Scholar 

Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, et al. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018;378:2376–2385

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013;14:834–842

Article  CAS  PubMed  PubMed Central  Google Scholar 

Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, et al. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children’s Oncology Group, multicentre, phase 3 trial. Lancet Oncol. 2019;20:719–727

Article  PubMed  PubMed Central  Google Scholar 

Haeberle B, von Schweinitz D. Treatment of hepatoblastoma in the German cooperative pediatric liver tumor studies. Front Biosci (Elite Ed). 2012;4:493–498

Article  PubMed  Google Scholar 

Eiso H, Tomoro H, Kenichiro W, Kohmei I, Yuka U, Sho K, et al. Outcome and late complications of hepatoblastomas treated using the Japanese study group for pediatric liver tumor 2 protocol. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.19.01067

Article  Google Scholar 

Wild CP, Montesano R. A model of interaction: aflatoxins and hepatitis viruses in liver cancer aetiology and prevention. Cancer Lett. 2009;286:22–28

Article  CAS  PubMed  Google Scholar 

Li W, Guo L, Rathi P, Marinova E, Gao X, Wu M-F, et al. Redirecting T cells to Glypican-3 with 4–1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity. Hum Gene Ther. 2017;28:437–448

Article  CAS  PubMed  PubMed Central  Google Scholar